Starting with the grand piano on stage, a charming blue carpet and the theater curtains opening projected on the big ledwall, the leitmotiv of the 8th EEMEA Partnership Meeting was unmistakably clear.
It was the “theater theme” that worked as the fil rouge of the event, specifically the opera house – an authentic Italian excellence.
Werfen and AFMS organized the first Partnership meeting held from March 22nd to March 24th in Dubai, UAE.
The cooperation between Werfen and its local KSA partner, AFMS, is unique.
In April, we launched our podcast channel EEMEA Talks with a first series on the History of Hemostasis.
Following a very successful launch of Aptiva in 2021, Werfen EEMEA had already installed the very first unit in December 2021.
The team did not rest on their achievement after this success, but instead became even more enthused, installing another unit in January 2022.
Dear Werfen Partners,
Werfen Academy in EEMEA is continuously growing in number of users and attended courses. Furthermore, a new competitors’ tool has just been released, so keep on reading this section until the end!
This is the third report since Werfen became a signatory member of the UN Global Compact. In it you will find all the initiatives we carried out in 2021 which contributed to the advancement of the UN Sustainable Development Goals (SDGs).
In 2022 we focused part of our effort to empower the care of women with bleeding and thrombotic disorders through education and social responsibility.
The year 2021 ended with EEMEA winning the BIO-FLASH tender in Serbia, with the big effort of our local distributor, Makler, against a tough competition. Thanks to this, Werfen would now be able to enter the Serbian market.
Many of you will probably have watched at least 1 episode of the Autoimmune Webinar Series that we launched in early 2020. But did you ever wonder how these webinars are made? For those who did, click read more for a short tour behind-the-scenes!
The International Congress on Antiphospholipid Antibodies (ICAPA) is held every three years to discuss recent advances and future directions in Antiphospholipid Syndrome (APS).

